Concepedia

Publication | Closed Access

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

DOI

649

Citations

29

References

2002

Year

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon, Christos Emmanouilides, Myron S. Czuczman, Mansoor N. Saleh, Larry D. Cripe, Gregory A. Wiseman, Teresa Olejnik, Pratik S. Multani,
Journal of Clinical Oncology

Abstract

Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic.

References

YearCitations

Page 1